BIOMAT Database Logo BIOMAT Database Logo

Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors. 2008

Arun K Ghosh, and Bruno D Chapsal, and Abigail Baldridge, and Kazuhiko Ide, and Yashiro Koh, and Hiroaki Mitsuya
Departments of Chemistry and Medicinal Chemistry, Purdue University, West Lafayette, Indiana 47907, USA. akghosh@purdue.edu

The synthesis of a series of stereochemically defined spirocyclic compounds and their use as novel P2-ligands for HIV-1 protease inhibitors are described. The bicyclic core of the ligands was synthesized by an efficient nBu 3SnH-promoted radical cyclization of a 1,6-enyne followed by oxidative cleavage. Structure-based design, synthesis of ligands, and biological evaluations of the resulting inhibitors are reported.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013141 Spiro Compounds Cyclic compounds that include two rings which share a single atom (usually a carbon). The simplest example of this type of compound is Spiro[2.2]pentane, which looks like a bow tie. Compounds, Spiro
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D016333 HIV Protease Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene. HIV Proteinase,HTLV-III Protease,p16 pol gene product, HIV,p16 protease, HIV,HIV p16 protease,HTLV III Protease,Protease, HIV,Protease, HTLV-III
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV

Related Publications

Arun K Ghosh, and Bruno D Chapsal, and Abigail Baldridge, and Kazuhiko Ide, and Yashiro Koh, and Hiroaki Mitsuya
Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors.
April 1998, Bioorganic & medicinal chemistry letters,
Arun K Ghosh, and Bruno D Chapsal, and Abigail Baldridge, and Kazuhiko Ide, and Yashiro Koh, and Hiroaki Mitsuya
HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.
September 2019, Journal of medicinal chemistry,
Arun K Ghosh, and Bruno D Chapsal, and Abigail Baldridge, and Kazuhiko Ide, and Yashiro Koh, and Hiroaki Mitsuya
Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands.
June 2011, Bioorganic & medicinal chemistry letters,
Arun K Ghosh, and Bruno D Chapsal, and Abigail Baldridge, and Kazuhiko Ide, and Yashiro Koh, and Hiroaki Mitsuya
Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
April 2006, Bioorganic & medicinal chemistry letters,
Arun K Ghosh, and Bruno D Chapsal, and Abigail Baldridge, and Kazuhiko Ide, and Yashiro Koh, and Hiroaki Mitsuya
Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
June 2014, Bioorganic & medicinal chemistry letters,
Arun K Ghosh, and Bruno D Chapsal, and Abigail Baldridge, and Kazuhiko Ide, and Yashiro Koh, and Hiroaki Mitsuya
Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands.
September 2014, Organic & biomolecular chemistry,
Arun K Ghosh, and Bruno D Chapsal, and Abigail Baldridge, and Kazuhiko Ide, and Yashiro Koh, and Hiroaki Mitsuya
Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands.
February 2019, Bioorganic & medicinal chemistry letters,
Arun K Ghosh, and Bruno D Chapsal, and Abigail Baldridge, and Kazuhiko Ide, and Yashiro Koh, and Hiroaki Mitsuya
Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.
September 2007, Journal of medicinal chemistry,
Arun K Ghosh, and Bruno D Chapsal, and Abigail Baldridge, and Kazuhiko Ide, and Yashiro Koh, and Hiroaki Mitsuya
Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation.
September 2019, Bioorganic & medicinal chemistry letters,
Arun K Ghosh, and Bruno D Chapsal, and Abigail Baldridge, and Kazuhiko Ide, and Yashiro Koh, and Hiroaki Mitsuya
Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
August 1996, Journal of medicinal chemistry,
Copied contents to your clipboard!